The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Outcomes of immune-checkpoint inhibitor rechallenge in urothelial carcinoma: Results from a global real-world evidence study.
 
Brigida Anna Maiorano
Research Funding - Merck
Travel, Accommodations, Expenses - Ipsen; Janssen; Novartis; Pfizer
 
Antonio Cigliola
No Relationships to Disclose
 
Valentina Tateo
Consulting or Advisory Role - Bayer
Travel, Accommodations, Expenses - Johnson & Johnson/Janssen; Merck
 
Chiara Mercinelli
Travel, Accommodations, Expenses - Johnson & Johnson/Janssen
 
Giovanni Luigi Pastorino
No Relationships to Disclose
 
Nazli Dizman
Stock and Other Ownership Interests - Several pharmaceutical companies (I)
Consulting or Advisory Role - Vivreon Biosciences
 
Hedyeh Ebrahimi
No Relationships to Disclose
 
Sumanta Pal
Speakers' Bureau - IntrinsiQ; MJH Life Sciences; Peerview
Travel, Accommodations, Expenses - crispr therapeutics; Exelixis; Ipsen
 
Shilpa Gupta
Stock and Other Ownership Interests - BioNTech SE; Moderna Therapeutics; Nektar
Consulting or Advisory Role - Astellas Pharma; Bayer; Bristol-Myers Squibb/Medarex; EMD Serono; Foundation Medicine; Genzyme; Gilead Sciences; Merck; Natera; Pfizer; Seagen
Speakers' Bureau - Bristol-Myers Squibb; Gilead Sciences; Seagen
Research Funding - Bristol Myers Squibb Foundation (Inst); EMD Serono (Inst); Exelixis (Inst); Gilead Sciences (Inst); Merck (Inst); Moderna Therapeutics (Inst); Novartis (Inst); QED Therapeutics (Inst); Roche/Genentech (Inst); Seagen (Inst)
Patents, Royalties, Other Intellectual Property - UpToDate author royalty
Travel, Accommodations, Expenses - Pfizer
 
Petros Grivas
Consulting or Advisory Role - Abbvie; Asieris Pharmaceuticals; Astellas Pharma; AstraZeneca; Bicycle Therapeutics; Bristol-Myers Squibb; CG Oncology; Daiichi Sankyo; EMD Serono; Fresenius Kabi; Gilead Sciences; ImmunityBio; Janssen; Merck; Pfizer; Replimune; Roche; Strata Oncology
Research Funding - Acrivon Therapeutics (Inst); ALX Oncology (Inst); Bristol-Myers Squibb (Inst); EMD Serono (Inst); G1 Therapeutics (Inst); Genentech (Inst); Gilead Sciences (Inst); Merck (Inst); Mirati Therapeutics (Inst); QED Therapeutics (Inst)
 
Ashish Kamat
Consulting or Advisory Role - Arquer Diagnostics; Asieris Pharmaceuticals; Aspira Women's Health (I); Astellas Pharma; AstraZeneca; CG Oncology; Cystotech; enGene; Ferring; Genentech; GlaxoSmithKline (I); ImmunityBio; Imvax; Janssen; Merck; Nonagen Bioscience; Pfizer; Seagen; Theralase; Valar Labs; Vivet Therapeutics
Research Funding - Arquer Diagnostics (Inst); enGene (Inst); FKD Therapies (Inst); Patient-Centered Outcomes Research Institute (PCORI) (Inst); Photocure (Inst); Seagen (Inst); SWOG (Inst)
Patents, Royalties, Other Intellectual Property - Patent: CyPRIT (Cytokine Predictors of Response to Intravesical Therapy) joint with UT MD Anderson Cancer Center
Other Relationship - Bladder Cancer Advocacy Network; European Urology Oncology; International Bladder Cancer Group (IBCG); Journal of Urology; UroToday
 
Philippe Spiess
Leadership - Global Society of Rare Genitourinary Tumors; NCCN; President of Global Society of Rare GU Tumors; Société Internationale d’Urologie Journal
Honoraria - UptoDate
Other Relationship - NCCN
(OPTIONAL) Uncompensated Relationships - Moffitt Cancer Center
 
Neeraj Agarwal
Research Funding - Amgen (Inst); Arvinas (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Celldex (Inst); crispr therapeutics (Inst); Eisai (Inst); Exelixis (Inst); Genentech (Inst); Gilead Sciences (Inst); Immunomedics (Inst); Janssen (Inst); Lilly (Inst); Merck (Inst); Nektar (Inst); ORIC Pharmaceuticals (Inst); ORIC Pharmaceuticals (Inst); Pfizer (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Exelixis; Pfizer
 
Andrea Necchi
Employment - Bayer (I)
Stock and Other Ownership Interests - Bayer (I)
Consulting or Advisory Role - AstraZeneca; Bicycle Therapeutics; Bristol-Myers Squibb; Catalym; Genenta Science; Gilead Sciences; Incyte; Johnson & Johnson/Janssen; Merck Serono; Merck Sharp & Dohme; Peerview; PeerVoice; Samsung Bioepis; Seattle Genetics/Astellas
Research Funding - Bristol-Myers Squibb/Celgene (Inst); Gilead Sciences (Inst); Merck Sharp & Dohme (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Gilead Sciences; Janssen; Merck Sharp & Dohme